Market revenue in 2023 | USD 7,685.9 million |
Market revenue in 2030 | USD 16,994.4 million |
Growth rate | 12% (CAGR from 2023 to 2030) |
Largest segment | Transdermal patches |
Fastest growing segment | Infusion Pumps |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Photodynamic Therapy Devices, Transdermal Patches, Wound Care Products, Infusion Pumps, Orthopedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters |
Key market players worldwide | Abbott Laboratories, Terumo Corp, Stryker Corp, Viatris Inc, Medtronic PLC, Boston Scientific Corp, Novartis AG ADR, Becton Dickinson & Co, Teleflex Inc, W L Gore & Associates |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug device combination products market will help companies and investors design strategic landscapes.
Transdermal patches was the largest segment with a revenue share of 23.34% in 2023. Horizon Databook has segmented the China drug device combination products market based on photodynamic therapy devices, transdermal patches, wound care products, infusion pumps, orthopedic combination products, drug eluting stents, inhalers, antimicrobial catheters covering the revenue growth of each sub-segment from 2018 to 2030.
The drug device combination products market in China is highly competitive due to the country’s high chronic disease burden. As per the Global Burden of Disease Study 2018, around 99 million people were diagnosed with COPD, and it has been the fifth leading cause of death in China. The rising interest of physicians in drug-device combination products to minimize the risk of heart & lung failure and speed up recovery is prompting manufacturers to develop specialized, safe, & effective devices.
With the high unmet needs of the growing population, the market is expected to witness significant growth over the forecast period. According to the National Bureau of Statistics of China, in 2023, individuals aged 60 & above accounted for around 19.8% of the national population by 2022. Moreover, with several healthcare reforms in China, the market is expected to exhibit substantial growth.
For instance, LifeSeeds, the China Rural Health Initiative (CRHI), is expected to provide healthcare access to unattended regions of China, creating opportunities for market players. Moreover, supportive regulatory and reimbursement policies are expected to boost the drug device combination products market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the China drug device combination products market , including forecasts for subscribers. This country databook contains high-level insights into China drug device combination products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account